Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT02238197 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

Start date: February 2001
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238184 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)

Start date: January 2001
Phase: N/A
Study type: Observational

To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238171 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Start date: April 2000
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238158 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Start date: September 1999
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

NCT ID: NCT02238145 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

Start date: January 1999
Phase: N/A
Study type: Observational

To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice

NCT ID: NCT02238132 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease

Start date: December 1998
Phase: N/A
Study type: Observational

To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

NCT ID: NCT02238119 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: February 2002
Phase: Phase 2
Study type: Interventional

Study to evaluate the lung function response to the free once-daily combination of tiotropium + formoterol compared to formoterol BID and tiotropium QD

NCT ID: NCT02238106 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The primary objective of this trial was to establish non-inferiority of lung function response to two doses [25 μg (1 capsule) and 50 μg (2 capsules of 25 μg)] salmeterol, administered as the xinafoate salt, in an inhalation powder delivered from hard polyethylene (PE) capsules via the HandiHaler® 2 compared to Serevent® Diskus® (salmeterol 50 μg, administered as the xinafoate salt) following single dose inhalation in patients with COPD. A hard capsule with half the strength (12.5 μg) was included to investigate a dose ordering effect. The secondary objectives were to characterize the pharmacokinetics of salmeterol inhalation powder delivered by HandiHaler® 2 from the PE hard capsule(s) and salmeterol xinafoate delivered by Serevent® Diskus®, and to compare the safety of the different pharmaceutical forms and/or doses.

NCT ID: NCT02238067 Completed - Clinical trials for Kidney Disease, Chronic

Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis

Start date: September 2011
Phase: N/A
Study type: Observational

This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in chronic kidney disease (CKD) treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis patient population in Israel. Participating physicians will be requested to complete a satisfaction survey for anemia treatment for eligible patients with CKD not on dialysis. The survey will be completed twice, once at study start and once at six months' follow-up.

NCT ID: NCT02236715 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Start date: September 1999
Phase: N/A
Study type: Observational

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice